MA38382A1 - Anticorps qui se lie a la sous-unite p19 de l'interleukine-23 humaine comprenant une chaine legere et une chaine lourde, utilise pour traiter ou prevenir par ex. La sclerose en plaques, la polyarthrite rhumatoïde, le psoriasis, le cancer et les maladies inflammatoires de l'intestin - Google Patents

Anticorps qui se lie a la sous-unite p19 de l'interleukine-23 humaine comprenant une chaine legere et une chaine lourde, utilise pour traiter ou prevenir par ex. La sclerose en plaques, la polyarthrite rhumatoïde, le psoriasis, le cancer et les maladies inflammatoires de l'intestin

Info

Publication number
MA38382A1
MA38382A1 MA38382A MA38382A MA38382A1 MA 38382 A1 MA38382 A1 MA 38382A1 MA 38382 A MA38382 A MA 38382A MA 38382 A MA38382 A MA 38382A MA 38382 A1 MA38382 A1 MA 38382A1
Authority
MA
Morocco
Prior art keywords
antibody
psoriasis
subunit
binds
cancer
Prior art date
Application number
MA38382A
Other languages
English (en)
Inventor
Catherine Brautigam Beidler
Stuart Willis Bright
Daniel Scott Girard
Kristine Kay Kikly
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38382A1 publication Critical patent/MA38382A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un anticorps qui se lie à la sous-unité pi 9 de il-23 humain et est caractérisé en ce qu'il a des propriétés d'affinité, de sélectivité et neutralisantes élevées. L'anticorps est utile dans le traitement ou la prévention d'une affection auto-immune ou inflammatoire choisie dans le groupe constitué de la sclérose en plaques, la polyarthrite rhumatoïde, le psoriasis, les syndromes abdominaux inflammatoires, la spondylarthrite ankylosante, une réaction de greffon contre hôte, le lupus et le syndrome métabolique. L'anticorps est également utile dans le traitement du cancer.
MA38382A 2013-03-08 2014-03-04 Anticorps qui se lie a la sous-unite p19 de l'interleukine-23 humaine comprenant une chaine legere et une chaine lourde, utilise pour traiter ou prevenir par ex. La sclerose en plaques, la polyarthrite rhumatoïde, le psoriasis, le cancer et les maladies inflammatoires de l'intestin MA38382A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774732P 2013-03-08 2013-03-08
PCT/US2014/020064 WO2014137962A1 (fr) 2013-03-08 2014-03-04 Anticorps qui se lient à il-23

Publications (1)

Publication Number Publication Date
MA38382A1 true MA38382A1 (fr) 2017-11-30

Family

ID=51488096

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38382A MA38382A1 (fr) 2013-03-08 2014-03-04 Anticorps qui se lie a la sous-unite p19 de l'interleukine-23 humaine comprenant une chaine legere et une chaine lourde, utilise pour traiter ou prevenir par ex. La sclerose en plaques, la polyarthrite rhumatoïde, le psoriasis, le cancer et les maladies inflammatoires de l'intestin

Country Status (40)

Country Link
US (3) US9023358B2 (fr)
EP (3) EP3789037A1 (fr)
JP (1) JP6096938B2 (fr)
KR (2) KR20170103037A (fr)
CN (1) CN105307681B (fr)
AP (1) AP2015008708A0 (fr)
AR (1) AR094877A1 (fr)
AU (1) AU2014226094B2 (fr)
BR (1) BR112015019611B1 (fr)
CA (1) CA2901462C (fr)
CL (1) CL2015002388A1 (fr)
CY (2) CY1123589T1 (fr)
DK (1) DK2964258T3 (fr)
EA (1) EA031524B1 (fr)
EC (1) ECSP15038626A (fr)
ES (1) ES2822662T3 (fr)
FI (1) FIC20230030I1 (fr)
FR (1) FR23C1036I1 (fr)
HK (1) HK1212252A1 (fr)
HR (1) HRP20201633T1 (fr)
HU (2) HUE051357T2 (fr)
IL (2) IL240731B (fr)
JO (1) JOP20140049B1 (fr)
LT (1) LT2964258T (fr)
MA (1) MA38382A1 (fr)
MX (1) MX370396B (fr)
MY (1) MY171226A (fr)
NL (1) NL301247I2 (fr)
PE (1) PE20151529A1 (fr)
PH (1) PH12015501994A1 (fr)
PL (1) PL2964258T3 (fr)
PT (1) PT2964258T (fr)
RS (1) RS60928B1 (fr)
SG (1) SG11201507176VA (fr)
SI (1) SI2964258T1 (fr)
TN (1) TN2015000348A1 (fr)
TW (1) TWI636063B (fr)
UA (1) UA123198C2 (fr)
WO (1) WO2014137962A1 (fr)
ZA (1) ZA201505285B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
WO2017074428A1 (fr) * 2015-10-30 2017-05-04 Eli Lilly And Company Anticorps bispécifiques anti-cgrp/anti-il-23 et leurs utilisations
AR111845A1 (es) 2017-05-03 2019-08-28 Lilly Co Eli Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
TWI808397B (zh) 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法
AU2020368369A1 (en) 2019-10-15 2022-05-12 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN115135671A (zh) 2019-12-20 2022-09-30 新石生物制药有限公司 抗白介素-23 p19的抗体及其使用方法
CN111718414B (zh) * 2020-06-12 2021-03-02 江苏荃信生物医药有限公司 抗人白介素23单克隆抗体及其应用
WO2022041390A1 (fr) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 Formulation liquide à faible viscosité comprenant un anticorps monoclonal anti-interleukine 23 humaine à concentration élevée, et son procédé de préparation
AR123477A1 (es) 2020-09-10 2022-12-07 Lilly Co Eli Formulaciones de anticuerpos terapéuticos
WO2022251623A1 (fr) 2021-05-28 2022-12-01 Eli Lilly And Company Régulation d'anticorps anti-il-23p19 de gènes impliqués dans la rectocolite hémorragique
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
WO2023056417A1 (fr) 2021-09-30 2023-04-06 Eli Lilly And Company Régulation d'anticorps anti-il-23p19 de gènes impliqués dans l'urgence intestinale dans la colite ulcéreuse
WO2024077113A1 (fr) 2022-10-06 2024-04-11 Eli Lilly And Company Méthodes de traitement de la fatigue liée à la colite ulcéreuse

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
NZ567860A (en) 2003-03-10 2009-11-27 Schering Corp Uses of IL-23 agonists and antagonists that specifically bind to IL-23R
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
SI1896073T1 (sl) 2005-06-30 2013-06-28 Janssen Biotech, Inc. Protitelesa proti il-23, sestavki, prostopki in uporabe
EA013506B1 (ru) * 2005-08-25 2010-06-30 Эли Лилли Энд Компани Антитело к il-23 и его применение
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
EP1931710B1 (fr) * 2005-08-31 2017-01-18 Merck Sharp & Dohme Corp. Anticorps anti-il-23 obtenus par genie genetique
EA035459B1 (ru) * 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
EP2064242A1 (fr) * 2007-02-23 2009-06-03 Schering Corporation Anticorps obtenus par génie génétiques dirigés contre l'il-23p19
PT2059534E (pt) * 2007-02-23 2012-07-17 Schering Corp Anticorpos anti-il-23p19 fabricados por engenharia genética
KR101123487B1 (ko) 2007-03-20 2012-03-23 일라이 릴리 앤드 캄파니 항?스클레로스틴 항체
CL2008001334A1 (es) * 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
WO2009082624A2 (fr) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci
EP2435480A1 (fr) * 2009-05-27 2012-04-04 Ablynx N.V. Produits de construction protéiques biparatopiques dirigés contre il-23
AP3953A (en) * 2010-11-04 2016-12-22 Boehringer Ingelheim Int Anti-IL-23 antibodies
RU2638806C2 (ru) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms способ мониторинга множественных реакций для выявления терапевтических антител в образцах животных с помощью каркасных сигнатурных пептидов

Also Published As

Publication number Publication date
HRP20201633T1 (hr) 2020-12-25
NL301247I2 (nl) 2023-11-01
CN105307681B (zh) 2018-06-26
JOP20140049B1 (ar) 2021-08-17
MX2015011959A (es) 2016-04-07
EP2964258B1 (fr) 2020-09-02
PH12015501994A1 (en) 2016-01-11
NZ711147A (en) 2021-03-26
CA2901462C (fr) 2017-07-25
EP2964258A4 (fr) 2016-10-12
US20140255422A1 (en) 2014-09-11
US9023358B2 (en) 2015-05-05
KR20150113202A (ko) 2015-10-07
LT2964258T (lt) 2020-10-12
CL2015002388A1 (es) 2016-03-04
CY1123589T1 (el) 2022-03-24
BR112015019611A2 (pt) 2017-08-22
KR20170103037A (ko) 2017-09-12
TWI636063B (zh) 2018-09-21
SI2964258T1 (sl) 2020-10-30
AU2014226094B2 (en) 2016-06-23
ZA201505285B (en) 2017-11-29
EP3789037A1 (fr) 2021-03-10
FR23C1036I1 (fr) 2023-12-08
KR101775115B1 (ko) 2017-09-05
US20170275356A1 (en) 2017-09-28
NL301247I1 (nl) 2023-10-11
IL272042B (en) 2021-07-29
AU2014226094A1 (en) 2015-08-27
DK2964258T3 (da) 2020-09-14
CA2901462A1 (fr) 2014-09-12
CN105307681A (zh) 2016-02-03
AP2015008708A0 (en) 2015-09-30
IL240731B (en) 2020-01-30
EA201591368A1 (ru) 2015-12-30
HUS2300036I1 (hu) 2023-11-28
JP2016510744A (ja) 2016-04-11
HUE051357T2 (hu) 2021-03-01
SG11201507176VA (en) 2015-10-29
ES2822662T3 (es) 2021-05-04
FIC20230030I1 (fi) 2023-10-03
JP6096938B2 (ja) 2017-03-15
RS60928B1 (sr) 2020-11-30
PE20151529A1 (es) 2015-10-28
PT2964258T (pt) 2020-11-06
EP4311558A2 (fr) 2024-01-31
WO2014137962A1 (fr) 2014-09-12
AR094877A1 (es) 2015-09-02
HK1212252A1 (en) 2016-06-10
MX370396B (es) 2019-12-11
MY171226A (en) 2019-10-03
US9688753B2 (en) 2017-06-27
CY2023021I1 (el) 2024-02-16
EA031524B1 (ru) 2019-01-31
PL2964258T3 (pl) 2021-02-08
EP4311558A3 (fr) 2024-04-10
EP2964258A1 (fr) 2016-01-13
US20150232552A1 (en) 2015-08-20
IL240731A0 (en) 2015-10-29
TN2015000348A1 (en) 2017-01-03
IL272042A (en) 2020-02-27
BR112015019611B1 (pt) 2023-05-02
UA123198C2 (uk) 2021-03-03
TW201520225A (zh) 2015-06-01
ECSP15038626A (es) 2015-11-30

Similar Documents

Publication Publication Date Title
MA38382A1 (fr) Anticorps qui se lie a la sous-unite p19 de l'interleukine-23 humaine comprenant une chaine legere et une chaine lourde, utilise pour traiter ou prevenir par ex. La sclerose en plaques, la polyarthrite rhumatoïde, le psoriasis, le cancer et les maladies inflammatoires de l'intestin
MA34642B1 (fr) Anticorps dirigé contre le tweak humain et leurs utilisations
CU24606B1 (es) Moléculas de anticuerpo que se unen a cd73
PE20181089A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
EA201000424A1 (ru) Антитела к il-23
ATE475672T1 (de) Anti-il-23-antikörper
EA201370105A1 (ru) Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a)
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
MA38986A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EA201390738A1 (ru) Нейтрализующие антитела против ccl20
EA201791973A1 (ru) Производные бензимидазола в качестве ингибиторов бромодомена
NO20083715L (no) Antistoffer mot human IL-22 og anvendelser derav
PH12015502090B1 (en) Pan-elr+cxc chemokine antibodies
WO2016173605A8 (fr) Neutralisation ultra-puissante de cytokines par des anticorps multispécifiques et utilisations associées
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA202192488A1 (ru) Антитела против tsg-6 и их применения
WO2015187521A3 (fr) Anticorps anti-blys
CL2023002393A1 (es) Anticuerpos anti-cd30l y usos de estos
MA44227A (fr) Anticorps pour il-17c
JP2017532332A5 (fr)
AR064713A1 (es) Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
EA202192008A1 (ru) Lilrb3-связывающие молекулы и варианты их применения
EA201890741A1 (ru) Биспецифические антитела против cgrp/il-23 и их применения
AR106231A1 (es) Anticuerpos anti-cd19 humano con alta afinidad